AIM ImmunoTech Gets Patent Pairing Its Cancer Drug With Keytruda
The broadest claim covers any cancer where the two drugs work better together than apart. Ampligen has not received FDA approval to treat any form of the disease.
ticker-aim
1 storyCoverage